Ruxience (rituximab)

pCPA File Number: 21186
Negotiation Status:
Concluded with an LOI
Indication(s):
Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)
Sponsor/Manufacturer:
Pfizer Canada ULC
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded: